hOMSC200

Phase 1Biologic

CCytora Ltd.

hOMSC200 is one of 36 biologic programs targeting Diabetic Foot. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Diabetic FootActive, not recruiting

Diabetic FootPhase 1

Active, not recruiting

Competition

Competitive Landscape

49 competitors in Diabetic Foot

#DrugCompanyPhaseTrials

Desferal

Remodulin

Vancocin

HHikma Pharmaceuticals LLC

Approved

3 4

Januvia

ZZydus Therapeutics Inc.

Approved

1 5

Caverject

VViatris Specialty LLC

Approved

—6

Sporanox

SSebela Pharmaceuticals Development LLC

Inomax

Tobrex

VViatris Specialty LLC

Approved

—9

Nitrostat

VViatris Specialty LLC

Approved

—10

Acetadote

AArbor Pharmaceuticals, Inc.

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Diabetic Foot1 trial

Study for Treatment of Chronic Diabetic Foot Ulcers With the Investigational Allogeneic Cell Therapy Product, hOMSC200

Active, not recruiting·CCytora Ltd.·Phase 1·NCT06003530·21 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for hOMSC200. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — hOMSC200 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for hOMSC200. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cytora Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: CCytora Ltd.

hOMSC200

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Diabetic Foot1 trial

References

Drug Info

Quick Facts

Related News